Posted by Michael Wonder on 14 Aug 2018
NICE would welcome further discussions about access to spinal muscular atrophy drug nusinersen
14 August 2018 - NICE hopes for further talks over nusinersen for treating a rare genetic disorder; spinal muscular atrophy.
Draft guidance does not recommend nusinersen, also called Spinraza and made by Biogen, for routine use on the NHS because of uncertainties over its long-term effectiveness and its extremely high cost.
The committee concluded that, based on its list price, the cost-effectiveness estimates for nusinersen ranged between £400,000 and £600,000 per year of quality adjusted life gained. Even with a proposed confidential price reduction the cost of nusinersen is too high for it to be considered a cost-effective use of NHS resources.
